Breaking: Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study.
Aptevo Therapeutics Inc
Biotechnology Research
Seattle, WA 3,409 followers
Our innovative ADAPTIR™ platform technology brings a unique approach to cancer immunotherapy and improves outcomes.
About us
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST. At Aptevo Therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning Aptevo Therapeutics to develop the science of what’s next in biotechnology.
- Website
-
http://www.aptevotherapeutics.com
External link for Aptevo Therapeutics Inc
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Seattle, WA
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
Get directions
2401 4th Avenue, Suite 1050
Seattle, WA 98101, US
Employees at Aptevo Therapeutics Inc
Updates
-
A warm congratulations and wishes for all the best to Aptevo board member, Barbara Lopez Kunz, who has been appointed CEO of Caidya.
Dr. Lingshi Tan transitions to Executive Chairman as Barbara Lopez Kunz steps up as CEO. Dr. Tan expressed his confidence in Barbara, noting her exceptional leadership skills and strategic vision. Here's to new beginnings and continued success at Caidya #ExecutiveLeadership https://ow.ly/pznG50SKCFH
-
-
APVO is at the BIO International Convention this week, hanging out with more than 18,000 biotechnology industry peers from around the world. #APVO #Partnering #WeHateCancer
-
-
We are onsite at the Life Science Innovation Northwest conference today. Aptevo COO, Jeff Lamothe, presented our differentiated and derisked Bispecifics story to a standing room crowd. Thank you #LSIW for the opportunity. #APVO, #bispecifics, #wehatecancer
-
-
Aptevo walks for a cure. Aptevo works for a cure. #APVO #Wehatecancer
-
-
Aptevo Therapeutics Inc reposted this
We walk to show solidarity. We work to find a cure. Making Strides Seattle 10.21.23 #APVO #WeHateCancer
-